Three-drug combination highly effective in patients with high-risk forms of chronic lymphocytic leukemia

A three-drug combination that sent chronic lymphocytic leukemia (CLL) into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.

Related Keywords

Rhode Island ,United States ,American ,Christine Ryan ,Matthew Davids ,Emily Henderson ,American Society Of Hematology ,Genentech ,Lifespan Health System ,Beth Israel Deaconess Medical Center ,Dana Farber Cancer Institute ,American Society ,Discovery Industry Focus ,Blood ,One ,Bone Marrow ,Dancer ,Children ,Hronic ,Chronic Lymphocytic Leukemia ,Clinical Trial ,Hospital ,Leukemia ,Research ,